UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 20, 2015

 

GENOCEA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

(Registrant’s telephone number, including area code): (617) 876-8191

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On May 20, 2015, Genocea Biosciences, Inc. (the “Company”) issued a press release announcing top-line data from the Company’s Phase 2 dose optimization trial evaluating the immunotherapy GEN-003 for the treatment of genital herpes. A copy of the press release, dated May 20, 2015, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

 

The information contained in this Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

 

Item 8.01 Other Events.

 

On May 20, 2015, the Company gave a presentation to certain investors regarding the top-line data from the Company’s Phase 2 dose optimization trial evaluating the immunotherapy GEN-003 for the treatment of genital herpes.  A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference.  The presentation is also available on the Company’s website, www.genocea.com, however the Company’s website and any information contained on the website are not incorporated herein.

 

Item 9.01 Financial Statements and Exhibits.

 

See Exhibit Index attached hereto.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		GENOCEA BIOSCIENCES, INC.
	By:	/s/ Jonathan Poole
		Jonathan Poole Chief Financial Officer

Date: May 20, 2015

 

3

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press Release issued by Genocea Biosciences, Inc. on May 20, 2015
99.2		Investor Presentation dated May 20, 2015

 

4